Relmada Therapeutics, Inc. RLMD
3.83
0.02
0.52%
as of 25 Sep
- Market cap
- $406.4M
- P/E
- 0.0×
Follow RLMD
Insider Buys
alert about insiders buying in the last 12 month
| Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 | Dec '20 | Dec '19 | Jun '19 | Dec '18 | Jun '18 | |
|---|---|---|---|---|---|---|---|---|---|---|
Current Ratio |
14.62 | 4.45 | 8.00 | 12.26 | 14.83 | 9.37 | 80.22 | 3.83 | 0.46 | 0.46 |
Net Debt/EBITDA |
1.57 | 0.54 | 0.93 | 0.92 | 1.69 | 1.92 | 7.71 | 0.76 | (0.06) | (0.07) |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 87.15% | 87.15% |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.48) | (0.48) |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF/Net income |
0.80 | 0.65 | 0.52 | 0.66 | 0.73 | 0.47 | 0.81 | 0.61 | 0.67 | 0.67 |
Capex/Depreciation |
— | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (0.01) |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| (94.05%) | (132.33%) | (87.51%) | (90.07%) | (80.14%) | (53.74%) | (24.34%) | (1,649.19%) | 162.54% | 442.21% | |
| (82.08%) | (111.57%) | (78.89%) | (83.48%) | (73.64%) | (50.53%) | (23.56%) | (261.05%) | (293.98%) | (304.53%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(65.54%) | (225.27%) | (115.80%) | (111.85%) | (60.39%) | (56.37%) | (12.99%) | (234.50%) | 284.06% | 284.06% |
Average Days of Receivables |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | — | 0.00% |
Free Cash Flow per Share |
(1.16) | (1.72) | (1.72) | (3.50) | (5.23) | (1.78) | (1.31) | (1.66) | (1.91) | (1.92) |
Cash per Share |
2.36 | 1.49 | 3.20 | 5.01 | 12.07 | 7.51 | 12.60 | 1.46 | 0.71 | 0.71 |
Shareholders Equity per Share |
2.19 | 1.18 | 2.84 | 4.74 | 11.87 | 6.77 | 12.52 | 1.21 | (1.76) | (1.76) |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
2.19 | 1.18 | 2.84 | 4.74 | 11.87 | 6.77 | 12.52 | 1.21 | (1.76) | (1.76) |
Free Cash Flow |
(45.79) | (51.76) | (51.66) | (103.80) | (91.87) | (27.81) | (12.09) | (10.50) | (6.00) | (6.01) |
Working Capital |
87.55 | 35.50 | 85.31 | 140.40 | 208.24 | 105.47 | 115.48 | 7.38 | (3.17) | (3.17) |
Capital Expenditures |
— | — | — | — | — | — | — | — | (0.01) | (0.01) |
Net Current Asset Value |
86.49 | 35.50 | 85.31 | 140.40 | 208.24 | 105.47 | 115.48 | 7.38 | (5.82) | (5.82) |
| Other line items | ||||||||||
Quick Ratio |
14.46 | 4.36 | 7.90 | 11.94 | 14.08 | 9.30 | 79.93 | 3.63 | 0.39 | 0.39 |
Depreciation/Fixed assets |
— | — | — | — | 0.00 | 2.92 | 0.88 | 92.50 | 0.21 | 85.27 |
Cash ROIC |
(25.51%) | (64.35%) | (28.43%) | (35.95%) | (21.87%) | (12.49%) | (5.21%) | (62.42%) | 973.64% | 973.64% |
Accounts Receivable Turnover |
— | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | 0.00 | 0.00 | 0.00 | — | 0.00 | — |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Operating CF per Share |
(1.16) | (1.72) | (1.72) | (3.50) | (5.23) | (1.78) | (1.31) | (1.66) | (1.91) | (1.91) |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Average Receivables |
— | — | — | 0.30 | 0.08 | 0.08 | 0.16 | 0.16 | 0.07 | 0.18 |
Average Payables |
2.85 | 3.82 | 4.38 | 8.23 | 9.77 | 4.43 | 0.72 | 0.84 | 0.77 | 0.65 |
Average Assets |
69.91 | 71.68 | 125.23 | 188.12 | 170.76 | 117.66 | 63.68 | 6.63 | 3.05 | 2.94 |
Average Common Equity |
61.02 | 60.44 | 112.90 | 174.35 | 156.92 | 110.63 | 61.65 | 1.05 | (5.51) | (2.03) |
Capex to Sales |
— | — | — | — | — | — | — | — | — | 0.00 |
Net Profit Margin |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Columns are period end dates